Saturday, 31 October 2026European Markets

SAS AB Stock Plunges Over 21% In Early Trading On Tuesday

Loading stream...

(VIANEWS) - Investors were unfavorably affected by SAS AB's latest financial results, sending shares plummeting by 21.68% to kr0.05 by 14:46 EST at 14:46 on Tuesday - its second consecutive session of losses. Meanwhile, Oslo Bors Benchmark Index_GI saw positive signs and climbed by 0.54% after three consecutive days of gains to close at 1,275.84. SAS AB's stock price last closed at kr0.06, or 86.79% below its 52-week high of kr0.47. This drop has caused great concern among investors who await news about what will be done to rectify the situation by SAS AB. Even after its recent setbacks, some analysts remain positive about SAS AB's long-term prospects. They cite its strong brand and solid financial standing as justifications. Other analysts may be more cautious; they cite challenging business environments and increased competition as potential concerns. Investors will closely track SAS AB's actions moving forward to see how it addresses recent setbacks and positions itself for future growth.

About SAS AB

SAS AB (publ) is a passenger flight transportation company operating within Nordic and international routes. Services provided include air cargo transport, inflight sales, ground handling services, technical maintenance solutions and travel-related loyalty programs. Established in 1946 and with 134 aircraft between long-haul (16), short-haul (87) and regional production partner aircraft (31) under its fleet ownership; SAS was initially headquartered out of Stockholm Sweden until July 5, 2022 when their affiliates filed voluntary petition for Chapter 11 bankruptcy protection under U.S. Bankruptcy Court for Southern District New York jurisdiction

Yearly Analysis

As a language model AI, I can offer you an analysis of SAS AB stock based on the information provided. However, please be aware that my analysis should not be seen as an assurance of future performance and should be used only as such. SAS AB's stock currently trades at kr0.05, considerably below its 52-week high of kr0.47 but higher than its 52-week low of kr0.01, suggesting it has experienced significant loss over the last year. SAS AB's EBITDA stands at -389.12, signaling to investors that it may not become profitable anytime soon. This can be seen as a warning signal from investors as this indicates potential short term loss-making business operations. Overall, SAS AB's stock is currently trading below its 52-week high while above its 52-week low and operating at a loss. Investors should carefully consider this information when making investment decisions.

Technical Analysis

SAS AB's stock price has recently traded considerably higher than both its 50-day and 200-day moving averages, signalling an apparent upward trend in its price. This could be an indicator that investors looking to buy it may wish to consider doing so; however, keep in mind that stock prices can still be affected by factors like earnings reports and macroeconomic conditions that could impact how it performs in future trading sessions. This stock's volume is considerably higher than average, which could indicate increased interest from investors and could drive up its price. A higher volume can be taken as an indication that more investors are purchasing and selling shares of it, potentially driving its price up. SAS AB's volatility has been relatively consistent over the last month, averaging 5.97% intraday variation. But its weekly variation has spiked up significantly with an amplitude of 35.00% - possibly signalling investor uncertainty regarding its future direction, making trading riskier for traders. Overall, SAS AB's stock appears to be trading above both its short-term and long-term moving averages, with above-average volumes and fluctuating volatility levels. Investors should carefully consider these factors as well as any relevant news and events before making an investment decision.

Quarter Analysis

This analysis indicates that revenue has experienced an annualized compounded growth rate of 12.8% over the past 12 months, reaching 42.04B for assessment by investors. Revenue growth can be affected by various factors including sales volume, pricing strategies and market demand - for this reason investors should take note of additional financial metrics and industry trends to gain a comprehensive picture of overall financial health as well as any future growth potential in an organization.

Equity Analysis

Earnings per Share (EPS) is a financial metric used to assess how much profit a company generates per outstanding share of stock. SAS AB's trailing twelve months EPS was kr-0.66, suggesting it has experienced negative profit margins. This may alarm potential investors as this might suggest the company may not generate sufficient revenues to cover expenses. Investors may benefit from considering factors beyond EPS when assessing SAS AB's overall financial health and potential growth, such as revenue growth, profit margins and financial stability. Comparing its EPS against peers within its industry may also give additional context and help identify any competitive advantages or disadvantages that exist.

More news about SAS AB (SASNO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com